Elevated serum levels of soluble CD14 in HBeAg‐positive chronic HBV patients upon Peginterferon treatment are associated with treatment response

Pegylated IFNα (PEG‐IFN) is one of the treatment options for chronic HBV (CHB) patients. However, the high patient treatment burden and limited response rate together clearly ask for biomarkers to predict PEG‐IFN response. Soluble CD14 (sCD14) is considered a marker for immune activation and has bee...

Descripción completa

Detalles Bibliográficos
Autores principales: Dou, Yingying, van Montfoort, Nadine, van den Bosch, Aniek, Janssen, Harry L. A., de Man, Robert A., Buschow, Sonja I., Woltman, Andrea M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6852593/
https://www.ncbi.nlm.nih.gov/pubmed/31090247
http://dx.doi.org/10.1111/jvh.13127

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6852593/
https://www.ncbi.nlm.nih.gov/pubmed/31090247
http://dx.doi.org/10.1111/jvh.13127

Ejemplares similares